Claims for Patent: 11,185,535

Summary for Patent: 11,185,535

Title:	Amorphous kinase inhibitor formulations and methods of use thereof
Abstract:	Provided herein is an amorphous compound represented by Formula (I): ##STR00001## and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR.alpha. kinases, and oncogenic forms thereof.
Inventor(s):	Kaufman; Michael D. (Waltham, MA), Bone; Scott (Bend, OR), Bloom; Corey (Bend, OR), Jordan; Fred (Bend, OR)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/180,234
Patent Claims:	1. A pharmaceutically acceptable tablet for orally delivering 50 mg of a compound represented by Formula (I): ##STR00036## comprising: an intragranular blend, wherein the intragranular blend comprises: (i) a solid dispersion having 50 mg of the compound wherein the compound is present in amorphous form and hydroxypropyl methyl cellulose acetate succinate; (ii) about 25-35% by weight microcrystalline cellulose based on the total amount of the tablet; (iii) about 25-35% by weight of lactose or a hydrate thereof based on the total amount of the tablet; (iv) about 5% by weight of crospovidone based on the total amount of the tablet; (v) about 0.5% by weight of silicon dioxide based on the total amount of the tablet; and (vi) about 0.5% by weight of magnesium stearate based on the total amount of the pharmaceutical tablet; and an extragranular blend, wherein the extragranular blend comprises (i) about 0.5% by weight of silicon dioxide based on the total amount of the tablet; and (ii) about 0.5% by weight of magnesium stearate based on the total amount of the of the tablet wherein the tablet disintegrates in less than 1 minute as tested using USP <701> for uncoated tablets.